Comerica Bank Raises Stock Holdings in LeMaitre Vascular, Inc. $LMAT

Key Points

• Comerica Bank increased its stake in LeMaitre Vascular, Inc. by 5.2% in the first quarter, owning approximately 144,038 shares valued at $12.08 million.
• LeMaitre Vascular reported earnings of $0.60 per share, exceeding expectations, alongside a 15% revenue increase to $63.15 million year-over-year.
• The company declared a quarterly dividend of $0.20 per share, with a total annual yield of 0.8%, reflecting a dividend payout ratio of 38.83%.

Comerica Bank grew its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 5.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 144,038 shares of the medical instruments supplier's stock after purchasing an additional 7,124 shares during the period. Comerica Bank owned about 0.64% of LeMaitre Vascular worth $12,085,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Opal Wealth Advisors LLC purchased a new stake in LeMaitre Vascular during the first quarter worth about $26,000. NBC Securities Inc. purchased a new stake in LeMaitre Vascular during the first quarter worth about $36,000. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in LeMaitre Vascular during the first quarter worth about $50,000. US Bancorp DE increased its stake in LeMaitre Vascular by 36.0% during the first quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier's stock worth $117,000 after purchasing an additional 368 shares during the period. Finally, Blueshift Asset Management LLC purchased a new stake in LeMaitre Vascular during the first quarter worth about $232,000. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Performance

Shares of LMAT opened at $95.28 on Wednesday. The stock has a 50 day moving average price of $86.58 and a 200 day moving average price of $86.37. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of 46.25, a price-to-earnings-growth ratio of 2.51 and a beta of 0.79. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.57 by $0.03. The firm had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm's quarterly revenue was up 15.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.52 earnings per share. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Research analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 4th. Investors of record on Thursday, August 21st will be issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Thursday, August 21st. LeMaitre Vascular's dividend payout ratio is 38.83%.

Insiders Place Their Bets

In related news, Director John A. Roush sold 6,561 shares of the company's stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $92.55, for a total value of $607,220.55. Following the completion of the transaction, the director directly owned 2,916 shares of the company's stock, valued at $269,875.80. This represents a 69.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director David B. Roberts sold 10,815 shares of the business's stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $92.39, for a total value of $999,197.85. Following the completion of the sale, the director owned 17,976 shares of the company's stock, valued at approximately $1,660,802.64. This represents a 37.56% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 120,815 shares of company stock valued at $11,280,206. 9.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on LMAT shares. Cantor Fitzgerald boosted their price objective on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Barrington Research raised LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price objective for the company in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $97.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.